Welcome to the Roche Sponsored Lunch Symposium
Evaluating the Role of Oral SERDs in HR+ Breast Cancer.
You’re invited to an engaging and insightful symposium exploring the evolving role of next-generation oral selective oestrogen receptor degraders (SERDs) in the management of hormone receptor-positive (HR+) breast cancer.
As evidence continues to emerge across both the early and metastatic settings, clinicians are faced with new opportunities to integrate these therapies into practice and interpret an increasingly complex data landscape.
Join Dr Belinda Yeo (Chair), together with Dr Stephen Luen and Professor Elgene Lim, as they explore:
- The latest evidence supporting the use of next-generation oral SERDs in HR+ breast cancer.
- Emerging data across both the early and metastatic breast cancer settings.
- Practical considerations for interpreting clinical trial results and understanding where oral SERDs may fit within evolving treatment pathways.
- Interactive panel discussions following each presentation, concluding with a live Q&A, providing the opportunity to hear diverse clinical perspectives and ask questions of our expert faculty.
Don’t miss this opportunity to hear from leading breast cancer specialists, gain practical insights into the rapidly evolving evidence for oral SERDs, and connect with colleagues from across the oncology community. We look forward to seeing you there!
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Roche-sponsored Lunch Symposium.
Belinda Yeo
Conference Guest Speaker
Belinda Yeo
Conference Guest Speaker
Dr Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer.
She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays.
She is co-lead of the VCCC Research and Education of the Breast Tumour Stream, she is a clinical trial investigator and continues her translational research investigating improving personalisation and minimising toxicities for patients with breast cancer.
Stephen Luen
Symposium Guest Speaker
Stephen Luen
Symposium Guest Speaker
Stephen Luen is a Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre with specialist interests in breast cancer, sarcoma, and phase 1 trials.
He completed his PhD under the primary supervision of Professor Sherene Loi in 2021, investigating genomic landscapes and drivers in hormone receptor-positive, HER2-negative early breast cancers, and continues to work closely with the lab as a postdoctoral scientist.
His current research interests include the study of genomic and immune biomarkers in breast cancer, with a particular focus on investigating biological characteristics and developing clinical trials for high-risk subgroups of patients.
Additionally, he has research interests in Precision Oncology approaches and the clinical development of novel therapeutic agents through early-phase clinical trials.
Elgene Lim
Symposium Guest Speaker
Elgene Lim
Symposium Guest Speaker
Professor Elgene Lim is a medical oncologist and researcher with a focus on breast cancer research and treatment, and the Principal Cancer Theme Lead at the Faculty of Medicine, UNSW Sydney, and the inaugural National Breast Cancer Foundation Endowed Chair.
He completed his doctoral research, medical and oncology training in Melbourne. Findings from his PhD research under the mentorship of Geoffrey Lindeman and Jane Visvader at the Walter and Eliza Hall Institute, had a major impact on the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome.
He subsequently furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School under the mentorship of Eric Winer and Myles Brown, both internationally acclaimed leaders in breast cancer research and clinical trials, through fellowships from the Fulbright Foundation, National Health and Medical Research Council of Australia, and Royal Australasian College of Physicians.
Elgene currently oversees the breast oncology unit at The Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney. He also heads the Connie Johnson breast cancer research laboratory at the Garvan Institute of Medical Research. In partnership with their patients, their research spans the laboratory to clinical trials. The laboratory performs clinically focused research, including the evaluation of novel therapies, and overcoming resistance to hormone receptor-positive breast cancers. Their research is funded through Cancer Australia, NHMRC, Cancer Council NSW, and the National Breast Cancer, Love Your Sister, White Butterfly, Balnaves, Curran Foundation, and Garvan Research Foundation.
Elgene also seeks to improve healthcare more globally. At a local level, he volunteered as a physician to asylum seekers without access to Medicare. He currently works with the Asha Kiran Hospital in Orissa, India, on a longer-term strategy of expertise transfer and partnership with local doctors.